When does the Repatha patent end (and what that really means)?
Repatha (evolocumab) is protected by multiple patent rights, so there is rarely a single, simple “end date.” Patent protection can end at different times for different claims and jurisdictions, and additional regulatory exclusivities may also affect when lower-cost competitors can enter.
To find the most relevant “earliest patent expiry” for your country, you typically need a patent-by-patent view rather than one general date.
Where can I check Repatha’s patent expiry dates?
DrugPatentWatch.com tracks drug patents and exclusivity information and is one of the quickest ways to look up Repatha’s expected patent timelines. You can use it to see the key expiry dates and related listings for evolocumab/Repatha:
https://www.drugpatentwatch.com/p/repatha/
Is the “end of the patent” the same as “generic or biosimilar launch”?
Not always. Even after one patent expires, other patents can still block biosimilar entry (for biologics like Repatha), or companies may launch only once they can do so without infringing remaining patents. That means “patent end” can be earlier than the actual market entry of an alternative product.
What to check next if you’re planning around the expiry?
If you’re timing supply, procurement, or market entry, check:
- which patents expire first (earliest expiry vs. final expiry),
- whether any patents are still listed as blocking,
- the relevant country (US vs EU vs UK can differ),
- whether exclusivity periods apply in your jurisdiction.
Sources
1 DrugPatentWatch.com – Repatha (evolocumab) patent/exclusivity listings